Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ashland Completes Sale Of Drew Marine
Ashland has completed the sale of its global marine services business, Drew Marine, to JF Lehman & Co. for approximately $120m before tax. Ashland will use the net
Ashland has completed the sale of its global marine services business, Drew Marine, to JF Lehman & Co. for approximately $120m before tax. Ashland will use the net
Clariant has sold its specialty silicones business, including its Gainesville Florida facility, to SiVance, an affiliate of New York-based GenNx360 Capital Partners. GenNx360 is a private equity firm
PsychoGenics and AstraZeneca have entered into a drug discovery and development agreement to identify compounds that are likely to be useful for the treatment of certain Central Nervous
Cytokinetics has presented the data from two phase IIa clinical trials evaluating omecamtiv mecarbil (formerly CK-1827452), one in stable heart failure patients and one in patients with ischemic
Nuevolution has entered into a research collaboration with Novartis. Under the collaboration, Nuevolution will apply its proprietary Chemetics drug discovery technology to identify novel small molecule leads against
Evotec has reported that the acquisition of the controlling majority stake of Research Support International (RSIPL) has been successfully completed and that RSIPL is a 70%, majority owned
BioNeutral Group has signed a collaborative agreement to expand its relationship with the Chertoff Group. Under the agreement, Chertoff Group principal Jeffrey Runge, and deputy chief operating officer
Catalyst Pharmaceutical has executed a license agreement under which it has acquired exclusive worldwide rights to commercialise GABA aminotransferase inhibitors and derivatives of vigabatrin discovered by Northwestern University.
Advanced Life Sciences has reported positive results from an animal study involving its once-a-day, oral antibiotic Restanza (cethromycin) that was conducted to measure Restanza’s therapeutic efficacy in treating
POZEN has reported that the FDA has accepted the New Drug Application (NDA) for Vimovo (PN 400). Vimovo is a fixed-dose combination of enteric-coated naproxen, pain-relieving non-steroidal anti-inflammatory